Prof.dr. Marjolein van Egmond received her Ph.D. from University Medical Center Utrecht, The Netherlands (Prof. Dr. J.G.J. van de Winkel) in 2000. Her thesis focussed on the identification the function of the human Fc receptor for immunoglobulin A (FcaRI). Since FcaRI was identified as potential target for tumor therapy, the focus of the research shifted during her post-doc period at Medarex Europe towards FcaRI-induced antibody-mediated tumour killing by immune cells.
After her transfer to the VU Medical Center in 2000, she started her own research group in which activation of the immune system by antibodies is studied. One major research line focusses on the contribution of abnormal antibody responses to chronic inflammation and autoimmunity. The other main topic that is investigated in her lab is monoclonal antibody therapy of cancer. Her research has a translational approach, which is facilitated by her dual appointment at the Department of Surgery and the Department of Molecular Cell Biology and Immunology, which facilitates rapid translation of pre-clinical findings into clinical applications.